^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib

Excerpt:
For VEGF-A at baseline, patients with and without disease control had median baseline levels of 108.7 and 46.6 pg/mL, respectively (P = 0.0332) and VEGF-A levels were also significantly elevated in Choi responders (P = 0.0250).
DOI:
10.1186/1479-5876-9-120